This inventor holds 1 USPTO granted patent. Top assignees: Inserm (Institut National De La Santé Et De La Recherche Médicale), Institut Claudius Regaud, Universite Toulouse III – Paul Sabatier. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Sarah Figarol: Cancer Research and Patent Innovation.
Introduction
Sarah Figarol is an inventor associated with cancer research in Toulouse, France. Her patent work addresses resistance to kinase inhibitors, a significant challenge in cancer treatment.
Latest Patents
Figarol is named on 1 patent, titled “Methods for the Treatment of Cancers That Have Acquired Resistance to Kinase Inhibitors.” The invention describes using farnesyltransferase inhibitors, including Tipifarnib, alongside kinase inhibitors such as erlotinib. The reported research found that this combination eliminated drug-tolerant cells and prevented resistant clones from emerging in several cancer models, including EGFR-mutated, ALK-translocated, and BRAF-mutated cancers.
Career Highlights
Figarol’s listed affiliations include Inserm (French National Institute of Health and Medical Research) and Université Toulouse III – Paul Sabatier. Her patent reflects research into strategies for addressing acquired resistance to targeted cancer therapies.
Collaborations
Her named collaborators include Olivier Calvayrac and Gilles Favre. The patent’s findings describe work across multiple oncogenic models to investigate the potential of farnesyltransferase inhibition.
Conclusion
Sarah Figarol’s patent contribution focuses on combining farnesyltransferase inhibitors with kinase inhibitors as a potential approach to counter drug resistance in cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile